Search
Now showing items 2461-2470 of 2472
European Society of Radiotherapy and Oncology (ESTRO) strategy 2024-2026: Growth and diversification in a rapidly changing world.
(ELSEVIER IRELAND LTD, 2024-07-01)
In 2019, the European Society of Radiotherapy and Oncology (ESTRO) published its 2030 Vision "Radiation Oncology, Optimal Health, For All, Together". However, in 2020, the global pandemic, coinciding with the Society's ...
Environmentally dependent and independent control of 3D cell shape.
(CELL PRESS, 2024-05-28)
How cancer cells determine their shape in response to three-dimensional (3D) geometric and mechanical cues is unclear. We develop an approach to quantify the 3D cell shape of over 60,000 melanoma cells in collagen hydrogels ...
Radiographer training for screening of patients referred for Magnetic Resonance Imaging: A scoping review.
(ELSEVIER SCI LTD, 2024-05-01)
INTRODUCTION: Strict safety practices are essential to ensure the safety of patients and staff in Magnetic Resonance Imaging (MRI). Training regarding the fundamentals of MRI safety is well-established and commonly agreed ...
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers.
(SPRINGERNATURE, 2024-04-17)
Poor survival and lack of treatment response in glioblastoma (GBM) is attributed to the persistence of glioma stem cells (GSCs). To identify novel therapeutic approaches, we performed CRISPR/Cas9 knockout screens and ...
The Emerging Role of LPA as an Oncometabolite.
(MDPI, 2024-04-04)
Lysophosphatidic acid (LPA) is a phospholipid that displays potent signalling activities that are regulated in both an autocrine and paracrine manner. It can be found both extra- and intracellularly, where it interacts ...
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells.
(AMER ASSOC CANCER RESEARCH, 2024-05-01)
UNLABELLED: Patients with estrogen receptor-positive breast cancer receive adjuvant endocrine therapies (ET) that delay relapse by targeting clinically undetectable micrometastatic deposits. Yet, up to 50% of patients ...
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
(BMJ PUBLISHING GROUP, 2024-02-27)
BACKGROUND: Targeting of solid cancers with chimeric antigen receptor (CAR)-T cells is limited by the lack of suitable tumor-specific antigens and the immunosuppressive, desmoplastic tumor microenvironment that impedes ...
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
(Elsevier BV, 2024-03-19)
Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, ...
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.
(NATURE PORTFOLIO, 2024-01-16)
Molecular-glue degraders are small molecules that induce a specific interaction between an E3 ligase and a target protein, resulting in the target proteolysis. The discovery of molecular glue degraders currently relies ...
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
(AMER ASSOC CANCER RESEARCH, 2024-03-01)
UNLABELLED: The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus ...